Comparison 11. Anticoagulants versus control: symptomatic arterial thromboembolism.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
11.1 Symptomatic arterial thromboembolism: DOAC vs placebo	1	841	Risk Ratio (IV, Fixed, 95% CI)	0.57 [0.17, 1.94]
11.2 Symptomatic arterial thromboembolism: LMWH vs no thromboprophylaxis	5	4351	Risk Ratio (IV, Random, 95% CI)	0.78 [0.49, 1.22]
11.2.1 Dalteparin	2	2321	Risk Ratio (IV, Random, 95% CI)	0.90 [0.52, 1.53]
11.2.2 Nadroparin	2	1653	Risk Ratio (IV, Random, 95% CI)	0.38 [0.14, 1.03]
11.2.3 Enoxaparin	1	377	Risk Ratio (IV, Random, 95% CI)	1.54 [0.26, 9.11]
11.3 Symptomatic arterial thromboembolism: LMWH vs aspirin	2	781	Risk Ratio (IV, Random, 95% CI)	2.01 [0.37, 10.86]
11.4 Symptomatic arterial thromboembolism: LMWH vs warfarin	1	439	Risk Ratio (IV, Fixed, 95% CI)	9.04 [0.49, 166.92]
11.5 Symptomatic arterial thromboembolism: vitamin K antagonists vs placebo	1	311	Risk Ratio (IV, Fixed, 95% CI)	Not estimable
11.6 Symptomatic arterial thromboembolism: warfarin vs aspirin	1	440	Risk Ratio (IV, Fixed, 95% CI)	0.20 [0.01, 4.14]